High-Dose Convalescent Plasma for Treatment of Severe COVID-19

Autor(es):Mostrar menos -

De Santis, Gil C. ; Oliveira, Luciana Correa ; Garibaldi, Pedro M. M. ; Almado, Carlos E. L. ; Croda, Julio ; Arcanjo, Ghislaine G. A. ; Oliveira, Erika A. F. ; Tonacio, Adriana C. ; Langhi Jr, Dante M. ; Bordin, Jose O. ; Gilio, Renato N. ; Palma, Leonardo C. ; Santos, Elaine, V ; Haddad, Simone K. ; Prado Jr, Benedito P. A. ; Pontelli, Marjorie Cornejo ; Gomes, Rogerio ; Miranda, Carlos H. ; Martins, Maria Auxiliadora ; Covas, Dimas T. ; Arruda, Eurico ; Fonseca, Benedito A. L. ; Calado, Rodrigo T.

• Tipo de documento: Artigo Científico
• Fonte: Emerging Infectious Diseases; v. 28, n. 3, p. 8-pg., 2022-03-01.

Resumo

To assess whether high-dose coronavirus disease (COVID-19) convalescent plasma (CCP) transfusion may benefit patients with severe COVID-19, we conducted a multicenter randomized trial in Brazil. Patients with severe COVID- 19 who were within 10 days of initial symptom onset were eligible. Patients in the CCP group received 3 daily doses of CCP (600 mL/d) in addition to standard treatment; control patients received standard treatment only. Primary outcomes were death rates at days 30 and 60 of study randomization. Secondary outcomes were ventilator-free days and hospital-free days. We enrolled 107 patients: 36 CCP and 71 control. At day 30, death rates were 22% for CCP and 25% for the control group; at day 60, rates were 31% for CCP and 35% for control. Needs for invasive mechanical ventilation and durations of hospital stay were similar between groups. We conclude that high-dose CCP transfused within 10 days of symptom onset provided no benefit for patients with severe COVID-19. (AU)

• Processo FAPESP: 20/05367-3 - Uso de plasma de doador convalescente para tratar pacientes com infecção grave pelo SARS-CoV-2 (COVID-19)
• Beneficiário: Rodrigo do Tocantins Calado de Saloma Rodrigues
• Modalidade de apoio: Auxílio à Pesquisa - Regular